Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Jenny C Yang"'
Autor:
Harry L. Janssen, Young-Suk Lim, Hyung Joon Kim, Leonard Sowah, Cheng-Hao Tseng, Carla S. Coffin, Magdy Elkhashab, Sang Hoon Ahn, Anh-Hoa Nguyen, Diana Chen, Jeffrey J. Wallin, Simon P. Fletcher, Circe McDonald, Jenny C. Yang, Anuj Gaggar, Diana M. Brainard, Scott Fung, Yoon Jun Kim, Jia-Horng Kao, Wan-Long Chuang, Anna E. Brooks, P. Rod Dunbar
Publikováno v:
JHEP Reports, Vol 6, Iss 2, Pp 100975- (2024)
Background & Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and ant
Externí odkaz:
https://doaj.org/article/830efe33915b4c0397fd5c5452831890
Autor:
Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Henry L.Y. Chan, Maria Buti, Marc G. Ghany, Anuj Gaggar, Jenny C. Yang, George Wu, John F. Flaherty, G. Mani Subramanian, Stephen Locarnini, Patrick Marcellin
Publikováno v:
Hepatology Communications, Vol 4, Iss 1, Pp 8-20 (2020)
In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown.
Externí odkaz:
https://doaj.org/article/9554e258943144788e5c32360057cbb9
Autor:
Edward J. Gane, P. Rod Dunbar, Anna E. Brooks, Fangqiu Zhang, Diana Chen, Jeffrey J. Wallin, Nicholas van Buuren, Priyanka Arora, Simon P. Fletcher, Susanna K. Tan, Jenny C. Yang, Anuj Gaggar, Shyamasundaran Kottilil, Lydia Tang
Publikováno v:
Journal of Hepatology. 78:513-523
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7755c6a1096a5a1381f3283dec393bf7
https://doi.org/10.1016/j.jhep.2022.09.027
https://doi.org/10.1016/j.jhep.2022.09.027
Autor:
Anna S. Lok, Maria Buti, John F. Flaherty, G. Mani Subramanian, Fabien Zoulim, Anuj Gaggar, Geoffrey Dusheiko, George Y. Wu, Patrick Marcellin, Henry Lik-Yuen Chan, Jenny C. Yang, Stephen Locarnini, Marc G. Ghany
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 4, Iss 1, Pp 8-20 (2020)
Hepatology Communications, 2019, 4 (1), pp.8-20. ⟨10.1002/hep4.1436⟩
Hepatology Communications, Vol 4, Iss 1, Pp 8-20 (2020)
Hepatology Communications, 2019, 4 (1), pp.8-20. ⟨10.1002/hep4.1436⟩
International audience; In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e954f8d1cc2ab96618e101ee1c9b48a4
http://europepmc.org/articles/PMC6939500
http://europepmc.org/articles/PMC6939500
Autor:
William E. Delaney, Dara Burdette, Lazerwith Scott E, Henry Chan, Jenny C. Yang, Becket Feierbach
Current approved therapies for Hepatitis B Virus (HBV) effectively control viral replication but are rarely curative. Patients on suppressive therapy still harbor cccDNA and cessation of therapy leads to rapid viral rebound 1-3. Even after long-term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f6f990dc144add01352db0ffd9acef1
https://doi.org/10.21203/rs.3.rs-100058/v1
https://doi.org/10.21203/rs.3.rs-100058/v1
Autor:
Zhuangbo Mou, Jun Li, Qin Ning, Jun Qi Niu, Deyuan Jiang, Steven J. Knox, Shanming Wu, Polina German, Jianning Jiang, Wu Li, Yuemin Nan, Zhi Liang Gao, Zhongping Duan, Guiqiang Wang, Kathryn Kersey, Jin Lin Hou, Lun Li Zhang, Jenny C. Yang, Yongfeng Yang, Benedetta Massetto, Hong Tang, Lai Wei, Jun Cheng, Feng Lin, Peng Hu, Xiaoguang Dou, Min Xu, Qing Xie, Diana M. Brainard, Guozhong Gong, Jidong Jia, Lanjuan Li, Hongmei Mo, Jiaji Jiang
Publikováno v:
Journal of Gastroenterology and Hepatology. 33:1168-1176
BACKGROUND AND AIM Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA polymerase with pangenotypic potency. This phase 3b study evaluated the safety and efficacy of sofosbuvir + ribavirin ± peginterferon in Chinese p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64dfe8967a57a556adf872ff56712514
https://doi.org/10.1111/jgh.14102
https://doi.org/10.1111/jgh.14102
Autor:
Tsung-Hui Hu, Steven J. Knox, Chun-Jen Liu, Chi-Yi Chen, Horng-Yuan Wang, I-Shyan Sheen, Ting-Tsung Chang, Chi-Jen Chu, Jenny C. Yang, Gin-Ho Lo, Benedetta Massetto, Wan-Long Chuang, Diana M. Brainard, Ron-Nan Chien, Cheng Yuan Peng, Jyh-Jou Chen, Chohee Yun, Anu Osinusi, Deyuan Jiang, Gregory Camus, You-Chun Hsu, Kuo-Chih Tseng, Pei-Jer Chen, John G. McHutchison
Publikováno v:
Gastroenterology. 154:989-997
Background & Aims There have been reports of reactivation of hepatitis B virus (HBV) infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents. We performed a prospective study of risks and outcomes of HCV in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7986918e930780ab13f1896a148e8fe
https://doi.org/10.1053/j.gastro.2017.11.011
https://doi.org/10.1053/j.gastro.2017.11.011
Autor:
Charlotte Hedskog, Ming Lin, Evguenia S. Svarovskaia, Ronald Nahass, Eric Lawitz, Ziad Younes, Diana M. Brainard, Michael P. Ryan, Catherine A.M. Stedman, John G. McHutchison, Hadas Dvory-Sobol, Hongmei Mo, Edward Gane, Mark S. Sulkowski, Jenny C. Yang, Brian P. Doehle, Sophie Metivier
Publikováno v:
Hepatology Communications
S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15a515d3dbaecb6ea354970814db2b5
https://doi.org/10.1002/hep4.1060
https://doi.org/10.1002/hep4.1060
Autor:
Charlotte Hedskog, William E. Delaney, Diana M. Brainard, Michael D. Miller, Jenny C. Yang, Eric Lawitz, Angela Worth, Hongmei Mo
Publikováno v:
Antiviral Research. 140:151-157
The NS3 protease inhibitor (PI) GS-9256 has demonstrated antiviral activity in a monotherapy study and in combination with other DAAs for treatment of chronic hepatitis C virus (HCV) infection. The resistance profile of GS-9256 was investigated in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f40b7c1662f8d46e99e0cb359a24e1
https://doi.org/10.1016/j.antiviral.2017.01.015
https://doi.org/10.1016/j.antiviral.2017.01.015
Autor:
Bing Gao, Tsung-Hui Hu, Steven J. Knox, Jia-Horng Kao, Horng-Yuan Wang, Kimberly L. Garrison, Wan-Long Chuang, Jenny C. Yang, I-Shyan Sheen, Phillip S. Pang, Hongmei Mo, Cheng Yuan Peng, Yu-Chun Hsu, Ting-Tsung Chang, Gin-Ho Lo, Jyh-Jou Chen, Chi-Jen Chu, Rong-Nan Chien
Publikováno v:
Journal of Gastroenterology and Hepatology. 31:1323-1329
Background and aim Pegylated-interferon-alpha plus ribavirin is the current standard-of-care regimen for treating chronic hepatitis C virus (HCV) infection in Taiwan; however, interferon-based regimens can be poorly tolerated. The interferon-free, tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::939faad230dcb8072430943305829262
https://doi.org/10.1111/jgh.13305
https://doi.org/10.1111/jgh.13305